The ethical discussion about drugs is frequently brought up among vegans. The idea that we’re never entirely sure what’s inside certain painkillers, essential medicines, and even vaccines makes many vegans reluctant to use them, even when needed.
However, Paraveganio means that doubt no longer needs to be a factor when you need something to relieve mild to moderate pain or even when you have a fever.
Developed by a German pharmaceutical company, axunion, the certified drug contains 500 mg of paracetamol. It also holds Vegan society endorsement, acknowledging the fact that it contains no animal derivatives and has not been tested on animals. Incredibly, statistics from the Vegan Society show that around 75% of the most commonly prescribed medicines in the UK contain animal products. And of course many more are tested on animals.
What makes Paraveganio so vegan?
In traditional paracetamol tablets, we find the addition of magnesium stearate which is a salt of stearic acid and magnesium and often of animal origin. Paraveganio is different because the magnesium stearate used is of pure vegetable origin.
The bad news is that, unfortunately, Paraveganio is currently only available in Germany, but axunio intends to expand into other markets in the near future.
Make more vegan medicines
A campaign launched by the Vegan Society in 2017 calls on the UK government to encourage the development of drug production, and in particular the use of existing animal-free alternatives to prescription products containing animal-derived ingredients.
Following the convictions of this campaign, we have organizations, such as the French society Vegepharm and based in the United States Genexa who are pioneers in the clean medicine industry, working to develop medicines without animals. And last year, Genexa even managed to raise $60 million in funding for medical development. It was founded in 2016 by two fathers who believed the world needed cleaner medicine; those with which should contain only the essential active ingredients and no additional artificial content.
Commenting on the progress of Paraveganio, Ericka Durgahee, Chief Marketing Officer of The Vegan Society, said, “We are thrilled to see our Vegan brand for the first time on a vegan medicine. We know that many vegans struggle to find medications that both suit their needs and align with their beliefs, which can be a pain. However, axunio has shown how easy it is to create a brilliant vegan product and we can only hope that other pharmaceutical companies will follow suit and work to create more vegan medicines.